Statement Of Cash Flows [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Adjustments for finance income (cost)
613,000 EUR
264,000 EUR
Adjustments for decrease (increase) in trade and other receivables
29,000 EUR
921,000 EUR
Adjustments for increase (decrease) in trade and other payables
1,050,000 EUR
468,000 EUR
Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss
349,000 EUR
196,000 EUR
Adjustments for gain (loss) on disposals, property, plant and equipment
- EUR
16,000 EUR
Adjustments for gain (loss) on disposal of investments in subsidiaries, joint ventures and associates
147,000 EUR
130,000 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales or maturity of financial instruments, classified as investing activities
- EUR
522,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from exercise of warrants
- EUR
2,832,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.